Colorectal Cancer ‑ Treatments, Trials & Research
Colorectal cancer starts in the colon or rectum, usually from a precancerous polyp that develops mutations over years before becoming cancerous.
Colorectal cancer starts in the colon or rectum, usually from a precancerous polyp that develops mutations over years before becoming cancerous. In advanced cases, treatment is increasingly guided by tumor biomarkers rather than location alone. RAS and BRAF status helps determine if EGFR targeted therapy can work, HER2 status may open a targeted antibody drug conjugate option, and dMMR/MSI‑H status identifies a minority of tumors that respond especially well to immunotherapy.
In advanced cases, treatment is increasingly guided by tumor biomarkers rather than location alone.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics